Abstract
More than a decade since the demonstration that antiretrovirals used for pre-exposure prophylaxis (PrEP) were safe and effective in decreasing HIV transmission, these medications remain underused, but continue to be needed, given the persistent burden of incident HIV infection, particularly in multiple sub-Saharan African countries. In 2020, there were about 1·5 million new HIV infections globally, representing a decline of only 31% since 2010.1 Oral tenofovir-based PrEP is highly effective, but disparities remain due to lower PrEP uptake and adherence among populations disproportionately impacted by HIV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
